FDA Adds Rare Vision-Loss Warning To All GLP-1 Diabetes And Weight Drugs
30m
Developing
1
The Food and Drug Administration said Monday it is adding a warning about a rare form of serious vision loss, known as non-arteritic anterior ischemic optic neuropathy, to the labels of all GLP-1 diabetes and weight-loss drugs sold in the United States, including blockbuster brands Ozempic, Wegovy, Zepbound and Mounjaro. CBS News
